Understanding COVID-19 outcomes among people with intellectual disabilities in England

Sosenko, Filip, Mackay, Daniel, Pell, Jill P, Hatton, Chris ORCID: https://orcid.org/0000-0001-8781-8486, Jani, Bhautesh D, Cairns, Deborah, Ward, Laura, Henderson, Angela, Fleming, Michael, Nijhof, Dewy, Melville, Craig and CVD-COVID-UK/COVID-IMPACT Consortium (2023) Understanding COVID-19 outcomes among people with intellectual disabilities in England. BMC Public Health, 23 (1). 2099. ISSN 1471-2458

Preview	Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview
Preview	Supplemental Material Available under License Creative Commons Attribution. Download (371kB) | Preview

Abstract

Background Evidence from the UK from the early stages of the covid-19 pandemic showed that people with Intellectual Disabilities (ID) had higher rates of covid-19 mortality than people without ID. However, estimates of the magnitude of risk vary widely; different studies used different time periods; and only early stages of the pandemic have been analysed. Existing analyses of risk factors have also been limited. The objective of this study was to investigate covid-19 mortality rates, hospitalisation rates, and risk factors in people with ID in England up to the end of 2021. Methods Retrospective cohort study of all people with a laboratory-confirmed SARS-CoV-2 infection or death involving covid-19. Datasets covering primary care, secondary care, covid-19 tests and vaccinations, prescriptions, and deaths were linked at individual level. Results Covid-19 carries a disproportionately higher risk of death for people with ID, above their already higher risk of dying from other causes, in comparison to those without ID. Around 2,000 people with ID had a death involving covid-19 in England up to the end of 2021; approximately 1 in 180. The covid-19 standardized mortality ratio was 5.6 [95% CI 5.4, 5.9]. People with ID were also more likely to be hospitalised for covid-19 than people without ID. The main determinants of severe covid-19 outcomes (deaths and/or hospitalisations) in both populations were age, multimorbidity and vaccination status. The key factor responsible for the higher risk of severe covid-19 in the ID population was a much higher prevalence of multimorbidity in this population. AstraZeneca vaccine was slightly less effective in preventing severe covid-19 outcomes among people with ID than among people without ID. Conclusions People with ID should be considered a priority group in future pandemics, such as shielding and vaccinations.